Where does Dianthus Therapeutics's cash flow data come from?

Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'24	FY'23	FY'22
Net income	-$84.97M-95.1%	-$43.56M+25.1%	-$58.12M+18.3%
Depreciation and amortization	$96K-79.8%	$475K-67.5%	$1.46M-27.7%
Stock-based compensation	$12.89M+345%	$2.9M—	——
Change in accounts receivable	——	——	——
Change in other assets	$1.6M—	——	——
Change in deferred revenue	$2.39M—	$0-100%	$891K—
Non-cash operating lease expense	$316K+9.7%	$288K—	——
Net cash from operating activities	-$78.18M-112%	-$36.86M—	——
Capital expenditures	$105K—	——	$314K-75.2%
Purchases of investments	$413.71M+620%	$57.42M—	——
Proceeds from maturities/sales of investments	$127M+63.3%	$77.79M—	——
Net cash from investing activities	-$287.98M—	——	-$59.82M—
Proceeds from issuance of common stock	$39.2M—	$0—	——
Net cash from financing activities	$257.82M+86.2%	$138.44M+43.2%	$96.68M+7.9%
Net increase (decrease) in cash	-$109.37M—	——	——
Accounts Payable Accrued Expenses And Operating Lease Liabilities	$8.19M—	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$6.02M+323%	$1.42M—	——
Depreciation	$96K+41.2%	$68K—	——
Gain Loss On Investment In Former Related Parties	——	——	——
Deferred revenue	$2.39M—	$0-100%	$891K—
Increase (Decrease) in Other Operating Assets	$8.16M+695%	$1.03M+3,213%	$31K—
Increase (Decrease) in Prepaid Expense and Other Assets	$1.6M—	——	——
Increase Decrease In Receivable From Former Related Party	——	——	——
Operating lease right-of-use asset amortization	$316K+9.7%	$288K—	——
Payments for Capital Improvements	$105K-4.5%	$110K—	——
Proceeds From Sale And Maturity Of Available For Sale Securities	$127M—	——	——
Payments Of Issuance Costs Public Offering	——	——	——
Proceeds From Issuance Of Common Stock Public Offering	——	——	——
Proceeds From Warrant Exercises	——	——	——
Issuance Costs In Connection With Public Offering Included In Accounts Payable	——	——	——
Issuance Costs In Connection With Public Offering Included In Accrued Expenses	——	——	——
Receivable Associated With Exercise Of Stock Options	——	——	——
Free cash flow	-$78.29M-112%	-$36.97M—	——
Free cash flow	-$78.29M-112%	-$36.97M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Dianthus Therapeutics's cash flow data come from?: Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.